Outcomes with HLA-matched unrelated donor versus haploidentical hematopoietic cell transplantation
We investigated the outcomes after adult haploidentical (haplo) and matched unrelated donor (MUD) hematopoietic cell transplantation (HCT) in a single-center study (n = 452) including 276 MUD and 176 haplo transplants. Myeloablative (37%) and reduced-intensity conditioning (63%) were performed. Graft sources included peripheral blood (50%) and bone marrow (50%). GVHD prophylaxis included tacrolimus/methotrexate (53%) and post-transplant cyclophosphamide-based (47%). In MUD versus haplo HCT recipients, a similar incidence of neutrophil engraftment (18 vs 17 days, p = 0.895), grade II-IV acute GVHD (51% vs 50%, p = 0.773), relapse (26% vs 23%, p = 0.578), non-relapse mortality (22% vs 23%, p = 0.817), 1-year disease-free survival (62% vs 63%. p = 0.921), and 1-year overall survival (73% vs 74%, p = 0.744) were observed. Earlier platelet engraftment (22 vs 27 days, p < 0.001) and higher chronic GVHD (45% vs 35%, p = 0.040) were noted in MUD as compared to haplo HCT. Allogeneic transplantation should be done promptly whenever indicated, utilizing either matched unrelated or haploidentical donors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:65 |
|---|---|
| Enthalten in: |
Leukemia & lymphoma - 65(2024), 4 vom: 15. Feb., Seite 493-502 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mushtaq, Muhammad Umair [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8N3DW7272P |
|---|
| Anmerkungen: |
Date Completed 26.02.2024 Date Revised 26.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/10428194.2023.2300708 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366555782 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366555782 | ||
| 003 | DE-627 | ||
| 005 | 20240229154813.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10428194.2023.2300708 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1306.xml |
| 035 | |a (DE-627)NLM366555782 | ||
| 035 | |a (NLM)38164945 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mushtaq, Muhammad Umair |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcomes with HLA-matched unrelated donor versus haploidentical hematopoietic cell transplantation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2024 | ||
| 500 | |a Date Revised 26.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a We investigated the outcomes after adult haploidentical (haplo) and matched unrelated donor (MUD) hematopoietic cell transplantation (HCT) in a single-center study (n = 452) including 276 MUD and 176 haplo transplants. Myeloablative (37%) and reduced-intensity conditioning (63%) were performed. Graft sources included peripheral blood (50%) and bone marrow (50%). GVHD prophylaxis included tacrolimus/methotrexate (53%) and post-transplant cyclophosphamide-based (47%). In MUD versus haplo HCT recipients, a similar incidence of neutrophil engraftment (18 vs 17 days, p = 0.895), grade II-IV acute GVHD (51% vs 50%, p = 0.773), relapse (26% vs 23%, p = 0.578), non-relapse mortality (22% vs 23%, p = 0.817), 1-year disease-free survival (62% vs 63%. p = 0.921), and 1-year overall survival (73% vs 74%, p = 0.744) were observed. Earlier platelet engraftment (22 vs 27 days, p < 0.001) and higher chronic GVHD (45% vs 35%, p = 0.040) were noted in MUD as compared to haplo HCT. Allogeneic transplantation should be done promptly whenever indicated, utilizing either matched unrelated or haploidentical donors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Matched unrelated donor | |
| 650 | 4 | |a allogeneic hematopoietic stem cell transplantation | |
| 650 | 4 | |a haploidentical donor | |
| 650 | 4 | |a outcomes | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 650 | 7 | |a Tacrolimus |2 NLM | |
| 650 | 7 | |a WM0HAQ4WNM |2 NLM | |
| 700 | 1 | |a Shahzad, Moazzam |e verfasserin |4 aut | |
| 700 | 1 | |a Amin, Muhammad K |e verfasserin |4 aut | |
| 700 | 1 | |a Lutfi, Forat |e verfasserin |4 aut | |
| 700 | 1 | |a DeJarnette, Shaun |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Ramahi, Joe S |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Nausheen |e verfasserin |4 aut | |
| 700 | 1 | |a Bansal, Rajat |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelhakim, Haitham |e verfasserin |4 aut | |
| 700 | 1 | |a Shune, Leyla |e verfasserin |4 aut | |
| 700 | 1 | |a Abdallah, Al-Ola |e verfasserin |4 aut | |
| 700 | 1 | |a Abhyankar, Sunil H |e verfasserin |4 aut | |
| 700 | 1 | |a McGuirk, Joseph P |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Anurag K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia & lymphoma |d 1989 |g 65(2024), 4 vom: 15. Feb., Seite 493-502 |w (DE-627)NLM012624047 |x 1029-2403 |7 nnns |
| 773 | 1 | 8 | |g volume:65 |g year:2024 |g number:4 |g day:15 |g month:02 |g pages:493-502 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10428194.2023.2300708 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 65 |j 2024 |e 4 |b 15 |c 02 |h 493-502 | ||